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Introduction
Radiotherapy is the medical use of ionizing radiations to control or kill clono-
genic cells. In particular in the targeted radionuclide therapy the radioactivity
is administered to the patient internally. Non-uniform activity within the target
lesions and critical organs constitutes an important limitation for dosimetric esti-
mates in patients treated with tumor-seeking radiopharmaceuticals. On the other
hand, the Tumor Control Probability (TCP) and the Normal Tissue Complication
Probability (NTCP) are heavily affected by the distribution of the radionuclide in
the treated organ/tissue [19]. In this thesis a clever and straightforward method
for calculating the absorbed dose at a small scale is described. This new method
takes into account a non-uniform activity distribution in the target lesion/organ.
This method is based on:
• the macroscopic conversion factors from the number of disintegrations in
a source region, to the dose absorbed by a target region, called S-values,
which were calculated for the various organs using Monte Carlo simula-
tions, as defined in the standard MIRD approach [1] and reported in the
OLINDA/EXM software [15];
• on the number of voxels (volume elements), in the SPECT or PET 3D
image, corresponding to the target lesion/organ;
• on the SPECT or PET raw-count 3D array of the target lesion/organ.
Starting from these parameters, the only mathematical operation required to cal-
culate the internal absorbed dose at voxel level, is to multiply the raw-count 3D
array for a scalar value. Therefore, the CPU-intensive 3D convolution of the stan-
dard MIRD algorithm, fully described in the MIRD Pamphlet No. 17 [25], using
S-values at voxel level, is avoided.
A comparison between the new method and the standard MIRD approach was
performed considering four different spherical, homogeneous, mathematical phan-
toms, 131I and 90Y contaminated, for two voxel dimensions. In addiction, the
performance of the new algorithm was tested for 3D internal absorbed dose cal-
culations for four patients affected by hepatocellular carcinoma and treated with
90Y -bearing micro-spheres. The results obtained with the new and simple method
are illutsrated and discussed.
This thesis is organized as follows:
0. Introduction
First part: Use of ionizing radiations for tumor treatment: basic con-
cepts of radionuclide therapy
• Chapter 1: the concept of ionizing radiation is explained and its applications
are illustrated;
• Chapter 2: the definition of the absorbed dose is introduced and the world-
wide accepted radiobiologic linear quadratic (LQ) model is illustrated; the
main equation for determining the internal absorbed dose is provided and
the MIRD algorithm is explained; the method to practically determine all
the factors which contribute to the average target internal absorbed dose is
discussed;
• Chapter 3: the definition of Tumor Control Probability is introduced and
its derivation from the Poisson and the binomial statistics is illustrated;
the concept of Dose-Volume Histogram and its practical utility in radio-
therapy are discussed; the three computational approaches now available
for performing 3D dosimetry in a target lesion/organ with a non-uniform
activity distribution are presented: dose point-kernel convolution, Monte
Carlo radiation transport, MIRD approach using S-values at voxel level.
Second part: A simple method for the calculation of 3D internal ab-
sorbed dose distributions without the use of voxel S-values, point ker-
nels, or Monte Carlo simulations
• Chapter 4: theoretical considerations about the new, simple method are
presented;
• Chapter 5: the calculation of the 3D absorbed dose distribution is performed
for four different mathematical phantoms using the new method and the
MIRD 17 method; the results obtained are compared and discussed;
• Chapter 6: the 3D dosimetry is performed for four patients treated using
90Y -bearing micro-spheres for the hepatocellular carcinoma (HCC) ther-
apy, the results obtained using the new method are compared with those
obtained using the MIRD 17 method;
• Chapter 7: discussion of the results and conclusions;
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0. Introduction
• Appendix: a graphical user interface for performing the 3D internal ab-
sorbed dose calculation using the new method was implemented, its con-
dictions of use are illustrated.
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Part I
Use of ionizing radiations for tumor
treatment: basic concepts of
radionuclide therapy
1 Foundations about therapy with
radionuclides
1.1 A brief history of nuclear medicine
The investigations of W.C.Roentgen led to the characterization, in 1895, of the
penetrating radiations, named X rays, which had an enormous and immediate
impact in the fields of physics and medicine [1]. The subsequent discovery of
radioactivity in 1896 by A.H.Bequerel led to the application of the radioactive
materials in many industries and in medicine. The first discoveries and analyses
of potentially useful radioactive substancies, radium and polonium, were made
by Pierre and Marie Curie, afterwards many other radionuclides were discovered
and used for therapy of a number of diseases. In 1957 the 99mTc generator was
developed at the Brookhaven National Laboratory. The ability to distribute short-
lived radionuclides to sites distant from their point of production revolutionized
the nuclear medicine [1]. During the same years a comprehensive mathematical
model of the absorbed radiation dose calculation was developed by E.Quimby and
L.Marinelli. It was in 1958 that H.Anger invented the scintillation camera which
permits complex two- and three-dimensional imaging of the distribution and ki-
netics of radiopharmaceuticals in the body. In 1953 G.Brownell and H.H.Sweet
built a positron detector based on the detection of annihilation photons by means
of coincidence counting. However it was from 1999 that positron emitting radio-
pharmaceuticals would come into routine clinical use. Subsequently the use of
Positron Emission Tomography has spread [1].
1.2 General concepts on ionizing radiations
The ionizing radiations are characterized by energy high enough to ionize the
atoms they interact with. The minimum radiation energy needed for the ioniza-
tion depends on the element interacting with the ionizing particle. Radiations
with energy higher than 5 eV could be ionizing for most of the isolated elements,
while in some solid materials, especially in semiconductors, the ionization process
can occur also at energies lower than this value [2].
The quantity of energy and how to transfer it by the ionizing radiation to the
interacting medium depend on the characteristics of both ionizing radiation and
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medium. The ionizing radiations are classified into two categories: directly ioniz-
ing radiations and indirectly ionizing radiations.
The charged particles, such as electrons and protons, are directly ionizing radia-
tions because each particle interacts directly with the coulombian fields generated
by electrons and nuclei of the material they are crossing. As a result, as they pass
through the matter, they undergo a lot of impacts, in each of which they yield a
little fraction of their initial energy [2]. On the other hand uncharged particles,
such as photons, are indirecly ionizing radiations, because they yield part or all
their energy to other charged particles (atomic electrons, for example) able to
directly ionize the matter [2].
The path of a charged particle in a material is characterized by a costant pro-
cess of loss of energy, until the particle’s initial kinetic energy is reduced to a
no-ionizing value. The loss of energy of the charged particles is essentially due
to anelastic diffusion processes by atomic electrons and nuclei of the material
crossed, in particular it is influenced by the distance of the particle’s trajectory
from atomic electrons and nucleus [2]. If the charged particle passes at a distance
from the nucleus greater than the atomic radius, it interacts with the total elec-
trons field. In this case the energy transferred to the material is low and results in
the excitation of the atomic electrons. If the charged particle passes at a distance
from the nucleus of the magnitude of the atomic radius, it could interact with a
single atomic electron. In this case the energy transferred is much higher, result-
ing in the emission of an atomic electron called delta ray. Finally if the charged
particle passes at a distance from the nucleus lower than the atomic radius, it
interacts with the nuclear field, being strongly scattered. In this case the particle
could loose all its energy in Bremsstrahlung radiation.
In contrast with charged particles, when a photon crosses matter it has two pos-
sibilities: to interact and be absorbed or not to interact and cross all the material.
For this reason it is irrelevant to talk of photon path into a material, because it
is more appropriate to talk of photons attenuation. The processes a photon can
udergo are: Rayleigh diffusion, Compton scattering, pair production and pho-
toelectric effect [2]. Rayleigh diffusion is a process of elastic diffusion in which
the photon nor transfers energy to the atom, nor produces secondary particles.
After the impact the photon doesn’t change its energy, but it is only deflected.
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In a Compton scatter process the incident photon transfers part of its energy to
the expelled atomic electron and part to the diffused secondary photon. As soon
as the electron is expelled it yields energy to the material through ionizations
and excitations. The pair production corresponds to the creation of an electron-
positron pair at the point of disappearance of the incident photon. A minimum
photon energy of 1.02MeV is required to make the process energetically possible.
If the photon energy exceeds this value, the excess energy appears in the form of
kinetic energy shared by the electron-positron pair. Therefore, the process con-
sists of converting the incident photon into electron and positron kinetic energies.
At last the photoelectric effect happens when all the photon’s energy is absorbed
by an atomic electron which is expelled.
Figure 1.1: Linear particle accelerator and robotic positioning table for
radiotherapy.
Because of their ability to ionize matter, ionizing radiations are used for several
activities in medicine, science and industries. In particular in medicine they are
used for tumor radiotherapy and for radiodiagnostic. Radiotherapy is the medical
use of ionizing radiation to control or kill clonogenic cells, while radiodiagnostic
is the medical use of ionizing radiation for the identification of the nature and
4
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cause of a disease.
Different types of sources of radiation are used in radiodiagnostic such as X rays
tubes and radionuclides with short half-life which emit low energy photons.
In the external beam radiotherapy, the ionizing radiations (photons, electrons
and recently protons and heavy ions) are produced by linear accelerators and
vehiculated on the target from outside the patient. In figure 1.1 a linear par-
ticle accelerator and a robotic positioning table for radiotherapy are shown. In
the targeted radionuclide therapy the radioactivity is administered to the pa-
tient internally. Typical radionuclides employed are: 131I, 90Y , 153Sm and 177Lu.
Recently the possibility to use alpha-particles emitters (expecially 223Ra) in the
treatment of pain bone metastases has been studied. The alpha-particles are char-
acterized from high linear energy transfer (LET) and short particle path length.
These properties seems to be ideal for the ablation of minimal residuals or mi-
crometastatic diseases.
In this thesis the possibility to individually optimize the administration of the
amount of radionuclide in targeted radionuclide therapy is discussed and studied.
A new, simple method to calculate this quantity is developed and discussed.
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2 Effect of ionizing radiations
on human tissues : basic
concepts of radiobiology and
absorbed dose calculation
2.1 Radiobiology
The absorption of energy in living cells, due to the interaction of the ionizing
radiations with the living tissues, can induce molecular modifications that may
lead to the cell death. In nature the death of a few cells within a tissue or an
organ will not have, in general, a significant effect on its functionality. However,
as the deposition of energy icreases, more cells will die, and this can affect the
functionality of the tissue [3].
The DNA is the principal target responsible for radiation-induced biologic effects
[3]. The interaction of a ionizing particle with the DNA can cause a single- or
double-strand break. The single-strand breaks produce reparable sublethal cell
damages, while the double-strand breaks cause not-reparable lethal cell damages.
In the first case the probability of repair will depend on the time between two
subsequent breaks: if the time interval needed to repair the damage is longer than
that between the two single subsequent breaks, the damage is lethal, otherwise it
is reparaible.
The physical quantity related to the DNA cell damage is the absorbed dose. The
dose absorbed by a target can be defined as [4]:
D =
d
dm
. (2.1)
Where d is the energy transferred by the ionizing radiation to a mass dm. The
unit of absorbed dose is [E]1[m]−1. In MKS this unit is called gray (1Gy = 1J/kg).
According to the well known, worldwide accepted linear-quadratic (LQ) model,
when a cluster of N0 basal cells absorbs a dose D, the number of the surviving
cells Ns can be expressed by the following equation [5]:
Ns = N0e
−(αD+GβD2). (2.2)
2.2. Internal absorbed dose evaluation
Where α and β are parameters describing the tissue response to the ionizing
radiations, in particular α relates to the response to a fatal damage (double-
strand break) and β relates to the response to a not-fatal damage (single-strand
break), as shown in fig. 2.1. The Lea-Catcheside time factor G, is the term which
takes into account the probability of a DNA lethal damage by subsequent single-
strand breaks. The linear-quadratic formalism with its specific functional form
for the time factor G, takes into account the dose protraction or fractionation. G
is described by the equation [5]:
G =
2
D2
∫ ∞
−∞
D˙(t) dt
∫ t
−∞
e−λ(t−t
′) D˙(t′) dt′. (2.3)
Where D˙(t) is the dose rate function which tracks the change in dose rate as a
function of time during the treatment and λ is the repair rate constant. Generi-
cally the integrand on the t′ variable refers to the first of a pair of DNA breaks
required to produce a lethal lesion; the exponential term describes the reduction
in numbers of such single strand breaks through repair. Similarly, the integrand
on the t variable refers to the second DNA break which can interact with the
break produced earlier. G can take values from zero to one, with G = 1 for a
single acute dose. G < 1 means a reduction in cell killing due to the repair which
occurs during continuous low-dose rate irradiation and/or between fractions.
Taking into account equation 2.2, in principle, it is possible to choose a tissue
absorbed dose D such that the surviving fraction Ns, due to the treatment, will
be small enough to ensure the tumor control.
2.2 Internal absorbed dose evaluation
To estimate the average absorbed dose for all significant tissues due to a certain
amount of a radionuclide incorporated inside human body, one must determine
for each of them the quantity of energy absorbed per unit mass [1]. Depending
on the radionuclide used, particles of characteristic energy and abundance will be
given off at a rate dependent on the amount of the activity present.
The quantities needed for a calculation of the average absorbed dose are: energy
and number of particles per decay; activity and mass of the target region; energy
7
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Figure 2.1: Single-strand break (β parameter) in blue; double-strand
break (α parameter) in red.
absorbed fraction which is the fraction of emitted energy which is absorbed by the
target. When considering the target as a whole organ, for photons some of the
emitted energy will escape the target, for beta particles most energy is usually
considered to be absorbed because the maximum range of beta particles, used in
radiotherapy, in human body is a few mm (energy absorbed fraction takes value
1) [1].
In this work the nomenclature proposed in the MIRD Pamphlet No.21 [6], for the
quantities, parameters and symbols used, will be adopted.
The main equation for the calculation of the average dose-rate D˙(rT , t) absorbed
by a target region rT (for example an organ at risk), due to a source region rs
contaminated by a radionuclide (for example the treated organ), is [1], [6]:
D˙(rT , t) =
k A(rs, t)
∑
i niEi φi(rT ← rs, Ei, t)
M(rT , t)
. (2.4)
Where: A(rs, t) is the radionuclide activity in the source region, i.e. the number of
decays in the unit of time, ni is the number of radiations with energy Ei emitted
per nuclear transition, φ(rT ← rs, Ei, t) is the fraction of energy Ei emitted in
the source region rs at time t that is absorbed by the target region rT ,M(rT , t) is
the time-dependent mass of the target region and k is a proportionality constant
8
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in appropriate units.
The time integral of the equation 2.4 gives the average absorbed dose D(rT , TD)
in the target region rT due to the radionuclide activity in a source rs [1], [6]:
D(rT , TD) = k
∫ TD
0
A(rs, t)
M(rT , t)
∑
i
niEi φi(rT ← rs, Ei, t) dt. (2.5)
Generally TD = ∞ because the radionclides used in radionuclide therapy are
tipically short-lived radionuclides, therefore they will decay before being expelled
from the target.
Equation 2.5 is the main equation for the average cumulative absorbed dose.
2.2.1 Medical Internal Radiation Dose (MIRD) algorithm
In 1968 the Medical Internal Radiation Dose (MIRD) committee developed the so-
called MIRD algorithm [7]. This algorithm was developed primarily for radiation
protection purposes and for the use in estimating radiation doses received by
patients from administered radiopharmaceuticals. It has been used for many years
becoming the standard in internal dosimetry.
The MIRD equation for the calculation of the averaged target absorbed dose is a
re-arrangement of the equation 2.5. The average absorbed dose by a target region
rT can be written as [7]:
D(rT , TD) =
∑
s
A˜(rs, TD)S(rT ← rs). (2.6)
Where A˜(rs, TD) is the cumulated activity in a source region rs over the dose-
integration period TD which can be described by the equation [6]:
A˜(rs, TD) =
∫ TD
0
A(rs, t)dt. (2.7)
All other terms of the equation 2.5 are lumped in the S-value (whose dimensions
from equation 2.6 are [D][A]−1[t]−1), which can be described as [7]:
S(rT ← rs) = k
∑
i niEi φi(rT ← rs, Ei)
M(rT )
. (2.8)
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The S-value is the conversion factor from the number of disintegrations in a source
region rs, to the dose absorbed by a target region rT , under the condition of uni-
form activity distribution into the source region. In the classical MIRD equation
(2.6) the target mass M(rT ) does not change due to the radionuclide therapy.
This is a not always valid approximation. A typical example is the therapy of hy-
perthyroidism or thyroid carcinoma with 131I, where the target mass is reduced
due to the presence of the radionuclide in the target itself [8].
The knowledge of the S-value greatly facilitated the determination of D(rT , TD),
enabling the dose calculation by a two-factor multiplication.
The S-values are calculated with MonteCarlo simulations of the creation and
transport of ionizing radiations (charged and non-charged particles) through a
mathematical model of the reference human body called phantom. Within each
source organ the activity is assumed to be uniformly distributed. Therefore S-
values for uniform activity distribution have been tabulated for many different
radionuclides (ni and Ei) and for different anatomic models (adult male, female
and children with fixed shapes and masses M(rT ) of each organ [9]).
Over the time different phantoms were developed and used by the MIRD Com-
mittee as model of the human body. In the late 1950’s a spherical human-phantom
was used, with lots of little spherical organs [10]. With this phantom it was easy to
calculate S-values, but it wasn’t too realistic. In 1969 the Fisher-Snyder phantom
used a combination of geometric shapes to create a reasonably accurate anatomic
representation of the body [1], as shown in fig. 2.2. Radiation doses were calcu-
lated for adults with uniform radionuclide activity in any organ irradiating other
organs, thus the absorbed fractions for over 100 radionuclides were published by
the MIRD Committee (1978) [11]. Afterwards six other more realistic phantoms
(representing children and adults of various ages and of both genders) were de-
veloped by Cristy and Eckerman in 1987 [12] (fig. 2.2): based on this, since 1996,
the MIRDOSE software made accessible the S-values for reference man, reference
woman and the pediatric phantoms [13]. In 1995, Stabin et al [14] wrote a docu-
ment with a series of 4 new phantoms representing the standard adult female at
various stages of gestation (fig. 2.3). This enabled to calculate the dose absorbed
by the fetus which is an important issue in both nuclear medicine and other areas.
10
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Figure 2.2: Fisher-Snyder phantom (left), Cristy and Eckerman adult
male phantom (rigth).
Figure 2.3: Stabin adult pregnant female phantom.
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In conclusion, the MIRD method:
• enables an easy calculation of the average dose absorbed by an organ (mak-
ing the hypothesis of a uniform activity distribution into each source region)
when the S(rT ← rs) values are known;
• does not consider differences in the shape of the organs between the real
patient and the phantom;
• does not consider the differences in the mass of the organs between the real
patient and the phantom.
In the early 21 st century, the RAdiation Dose Assessment Resources (RADAR)
group established a web resource (www.doseinfo-radar.com) [10], [1] to provide
quick, worldwide dissemination of relevant quantities (decay data for over 800
radionuclides, absorbed fractions for all available stylized phantoms and other
informations) for the calculation of the absorbed dose. The same group produced
the OLINDA/EXM personal computer software code [15], a standard in the cal-
culation of internal absorbed dose which uses equation 2.6.
2.3 Practical methods for internal absorbed dose calculation
The algorithm for the internal absorbed doseD(rT , TD) calculation is described by
equation 2.6. This equation depends on two factors: the time-dependent (biokinet-
ics) factor A˜(rs, TD) and the time-independent (physical) factors, reported within
S(rT ← rs).
The value of S(rT ← rs) (described in equation 2.8) depends on the radionu-
clide used (factors ni and Ei), on the shape and the size of the source organ
(factor φ(rT ← rs, Ei)), on the shape and size of the target organ by both the
φ(rT ← rs, Ei) and M(rT ) values, and on the distance between rT and rs.
The method to determine the time-independent S(rT ← rs) value has already
been described in section 2.2.1. Discrepancies between the S-values calculated
with different Monte Carlo codes are reported in the recent work by Pacilio et al
[16]. These discrepancies may be due to the different radiation transport meth-
ods used, in particular to the different models for electron transport and multiple
12
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scattering theories.
The time-dependent cumulated activity A˜(rs, TD) incorporates characteristics of
both uptake and retention of the activity in the region of interest and takes into
consideration of the physical half-life of the radionuclide and the biological half-
life of the radiopharmaceutical [17].
To determine the time-dependent cumulated activity in the desired source re-
gions, serial measurements of activity must be made after the administration
of the radiopharmaceutical. The measurements can be performed using quanti-
tative imaging techniques including planar scintillation-camera, 3D-SPECT or
-PET. The resulting time-activity curve obtained for each source region can be
analyzed in order to calculate the cumulated activity A˜(rs, TD) [17].
The measurement procedure involves three phases [17]:
• Data collection: identification of the various source regions containing ac-
tivity; determination of appropriate temporal sampling and acquisition of
radioactivity or counts data;
• Data analysis: calculation of activity in source regions as a function of time
using data and calibration factors;
• Data processing: fit of the time-activity curves to obtain the sum of all
the nuclear transitions or the cumulated activity A˜(rs, TD) in each source
region.
After the source regions have been identified, the activity retention in these re-
gions must be determined. For further refinement, both the uptake phase and
the washout phase must be characterized accurately with serial activity measure-
ments. The uptake phase is the period over which the activity increases from zero
to its maximum value. It is often assumed that the uptake of the radiopharma-
ceutical is istantaneous [17] this approximation can be made when the uptake
phase is much lower than clearance.
The washout (clearance) phase is the period over which the activity retained in a
region decreases from its maximum value. This is due to the physical decay and
to the biologic elimination: thus the effective half-life of the radiopharmaceutical
is always more rapid than the physical [17].
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To characterize the long-term retention, measurements at times equal to multi-
ples of the effective half-life are needed. Frequently, this may be accomplished
within several hours post-administration [17].
Mathematical models that describe the kinetic processes of a particular agent
may be used to predict its behaviour in regions where direct activity measure-
ments are not possible, but where sufficient knowledge about the physiology of
the region is available to specify its inter-relationships with the regions or tissues
in which uptake and retention can be measured directly. Because many processes
in the body are governed by first-order kinetics, sums of exponentials are often
used as these mathematical models [17]. An adequate number of activity data
points should be measured, in order to properly characterize the mathematical
curve-fitting function or the multicompartmental model: ideally two or three mea-
surements per exponential term are required, and the timing between these points
should be carefully selected (the selection of the sampling time can have a signif-
icant effect on the precision of the parameter estimation [17]). As the number of
measurements increases, the confidence in the fit to the data and in the estimates
of unknown parameters in the model improves. The physical half-life of the ra-
dionuclide plays an important role in determining the period over which reliable
data may be obtained. After approximately five half-lives, count statistics can be
extremely poor, and the data may be less reliable.
Defining A(rj, 0) as the initial activity value of the source region rj interconnected
with the source region rs; λ as the physical decay constant of the radionuclide
and λj as the biologic elimination constant of the source region rj, the activity
measurements must be fitted to this equation to calculate A(rj, 0) and λj [17]:
A(rs, t) =
∑
j
A(rj, 0)e
−(λ+λj) t. (2.9)
Equation 2.9 is the general equation describing the time kinetics of the radionu-
clide in rs. It comes as solution of a compartmental model which represents the
interactions between organs/tissues uptaking the radionuclide [18]. Equation 2.9
must be used in the calculation of the cumulated activity A˜(rs, TD) (equation 2.7)
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A˜(rs, TD) =
∫ TD
0
A(rs, t) dt =
∑
j
A(rj, 0)
(λ + λj)
, (2.10)
where the combination of physical decay and biologic removal results in an expo-
nential disappearence rate that is the sum of the physical λ and the biologic λj
decay rates for each source region rj inter-connected with the source region rs.
The sum of λ and λj is called the effectve half-life of the radionuclide in rj [17].
Alternatively A˜(rs, TD) may be calculated as the area under the curve in the plot
of A(rs, t), by use of a numerical method.
Errors in estimates of A˜(rs, TD) may be introduced as a result of improper sam-
ple timing and an inadequate number of samples when analytical functions are
used to approximate the measured time-activity curve. It is often assumed that
the uptake of the radiopharmaceutical is istantaneous. Errors generated by this
assumption will result in an overestimate of the dose component from the source
region to various targets. Concerning the characterization of the long-term reten-
tion, if the data acquisition ends too early, the area under the curve would not be
representative of that under the true retention curve because the long-term reten-
tion phase would not be included. In summary, improper sampling may introduce
errors in calculated values of A˜(rs, TD) [17].
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3 Internal dosimetry of non-uniform
activity distributions
3.1 The Tumor Control (TCP) and the Normal Tissue Complica-
tions (NTCP) Probability
Much effort in radiotherapy is currently being devoted to the optimization of the
physical dose distributions in order to deliver the necessary dose to the tumor
without increasing the probability of damage to the normal tissues. The organs
close to the treatment target are often subjected to diffuse high dose, with con-
siderable potential for treatment-related complications [19].
The possibility to estimate the effect that a given absorbed dose will have on the
probability of tumor control (TCP) and on the possibility of complications in the
surrounding normal tissues (NTCP) is crucial in radiotherapy. For the therapeu-
tic outcome the TCP may be a more relevant quantity than the absorbed dose
[19].
TCP is the probability that no malignant cells are left in a specified location after
irradiation. This probability can be useful for the determination of a therapeutic
strategy where the dose to the target tumor is increased without increasing the
damages to the healthy tissues. The TCP depends on the radiation sensitivity of
the tissue, the basal number of cells in the tumor and the dose absorbed by the
tumor cells. Moreover it is heavily affected by the distribution of the radionuclide
in the treated organ/tissue [19]. Therefore non-uniform activity distribution plays
an important role in the estimation of the radiodosimetric burden to lesions and
to critical organs in patients treated with radionuclide therapy [19].
The Tumor Control Probability (TCP) can be theoretically derived from two sta-
tistical models, the Poisson statistic and the binomial distribution [20].
TCP derivation from Poisson statistics
If the number of cells present before the treatment N0 is large and if the cell
survival after the treatment is a rare event, the probability that k cells survive is
given by:
P (X = k) =
λk e−λ
k!
. (3.1)
3.1. The Tumor Control (TCP) and the Normal Tissue Complications (NTCP)
Probability
Where X denotes the random variable of the number of surviving cells. It is
assumed that the observed surviving cell number Ns is a good estimation of the
expected value of X, and hence we assume λ = Ns. The tumor control probability
denotes the probability of having no tumor cells and can been expressed as [20]:
TCP = P (X = 0) = e−Ns . (3.2)
This expression is only valid when the cell survival probability is small and the
number of cells surviving irradiation is much less than the initial number of tumor
cells, which are usual conditions in radiotherapy treatments.
TCP derivation from binomial statistics
Let p denote the survival probability of an individual cell. If we assume that all
cells are identical and independent, then we obtain from a binomial distribution:
P (X = k) =
(
n
k
)
pk (1− p)n−k. (3.3)
Again we assume that the observed surviving cell number is a good estimator
of the expectation of X, so E(X) = np = Ns. Considering this statement and
the equation 2.2 for the LQ model, the survival probability can be written as
p = e−(αD+βGD
2). In this case the TCP can be expressed as [20]:
TCP = P (X = 0) = (1− p)n. (3.4)
The limit of equation 3.4 as n → ∞ and p → 0, such that 0 < p < ∞, results
in the Poisson statistics expression 3.2.
If the dose dependence of the TCP is plotted, it generates the characteristical
sigmoidal curve. An example of this curve for TCP and NTCP, which can be
expressed as NTCP=1-TCP, is shown in figure 3.1. Although the normal tissue
curve is displaced to the right of that of tumor, this relatively favourable thera-
peutic situation illustrates that dose prescription nevertheless involve selecting a
risk-benefit ratio appropriate to the clinical situation.
The importance of avoiding low-absorbed dose regions in the tumor is clearly il-
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Figure 3.1: Sigmoidal curves of TCP and NTCP. Points A, B and C illus-
trate doses wich would give different ratios of tumor control
to complications.
lustrated by the rapid fall-off to zero of the TCP. When the value of D decreases,
the number of surviving clonogenic cells Ns increases and than TCP decreases.
Recently H.Uusijärvi, P.Bernhardt and E.Forssell-Aronsson published a study [19]
about how TCP depends on the radionuclide distribution in the tumor. The aim
of this study was to examine the possibility to control a tumor when the activity
distribution is non-uniform. The activity distribution and cellular geometry differ
between different tumors types and radiopharmaceuticals, and it is impossible to
create a model that applies to all situations. The activity distribution in the tumor
will depend on the tumor type, the radiopharmaceutical used and the perfusion
of the tumor, and will also vary with time. Non-uniform radionuclide distribution
can lead to a non-uniform absorbed dose distribution within the tumor and the
terapeutic efficacy might be negatively affected.
According to this study both the TCP and the NTCP are heavily affected by the
distribution of the radionuclide in the treated target organ/tissue. Therefore non-
uniform activity distribution plays an important role in the therapeutic efficacy
for patients treated with radionuclides [19].
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3.2 Dose-Volume Histogram
The knowledge of the target and normal healthy tissue fraction absorbing a cer-
tain dose value is very important to understand if the tumor can be controlled
and the other healthy tissues are damaged by the irradiation. This is due to the
dependence of TCP and NTCP on the target and healthy tissue absorbed dose
(figure 3.1). The Dose-Volume Histogram (DVH) is a concept very common in
external-beam radiotherapy because it is useful to predict the fraction of the tu-
mor and other tissues which absorb a certain dose value.
The purpose of a DVH is to summarize a 3D dose distribution in a graphical
2D format. Figure 3.2 shows an example of a differential DVH (above) and the
relative cumulative DVH (below) while in figure 3.3 there is an example of cumu-
lative DVH clinically used. It includes all structures and targets of interest in the
radiotherapy plan, each line plotted with a different colour represents a different
structure.
Figure 3.2: Differential DVH above and the relative cumulative DVH
below.
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Figure 3.3: Clinically used cumulative DVH.
In a differential DVH, column height indicates the volume of the organ receiv-
ing a dose given by the bin. In a cumulative DVH the column height represents
the volume of the organ receiving greater than or equal to that dose. In external
beam radiotherapy the cumulative DVHs are overwhelmingly used and preferred
over differential DVHs.
3.3 Methods for 3D internal absorbed dose calculation
As fully explained in section 2.2.1 the classical MIRD algorithm (equation 2.6) en-
ables the calculation of the average absorbed dose in a macroscopic target organ.
This follows from the hypothesis of uniform activity distribution in the source
organs. In many cases the non-uniform activity distribution plays an important
role in the estimation of the radiodosimetric burden to lesions and to critical or-
gans in patients treated with radionuclide therapy [21], [22], [23], [24]. Both the
TCP and the NTCP are heavily affected by the distribution of the radionuclide
in the treated target organ/tissue [19].
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Internal dosimetry provides methods for the calculation of absorbed dose from
radionuclides incorporated inside human body and can be performed over a broad
range of target dimensions: whole organs, suborgan regions, small-scale tissue re-
gions, multicellular clusters, single cell [25].
A three-dimensional (3D) dosimetry at a small scale is needed to obtain an ab-
sorbed dose map in a region (target organ/tissue) in which the activity distri-
bution of the employed radionuclide is non-uniform. At present, 3D PET- and
SPECT-CT images provide great opportunities. In fact, provided that some fac-
tors (attenuation correction, spatial resolution, reconstruction algorithms) are ad-
equately taken into account, these imaging modalities can yield reliable quantita-
tive three dimensional scintigraphic data. The 3D imaging-based internal dosime-
try methods are based on the anatomical CT and on the functional SPECT or
PET imaging modalities. The CT images are used to provide the density and
composition of the tissues and to define the Regions Of Interest (ROIs) in the or-
gans. The SPECT or PET images give information about the distribution of the
radiopharmaceutical into each voxel (volume element) of various organs, enabling
the possibility to calculate the activity and the effective half-life of the radionu-
clide in the body. Based on these two imaging modalities, 3D internal dosimetry
methods were developed to calculate the 3D-array which represent the map of
the distribution of the dose absorbed by the different regions of the tissues and
the DVHs over user-defined ROIs [22].
Currently three computational approaches are available for performing 3D dosime-
try in a non-uniform radioactivity distribution target:
• dose point-kernel convolution;
• direct Monte Carlo radiation transport;
• MIRD approach using S-values at voxel level.
Dose point-kernel approach:
A dose point-kernel represents the radial distribution of absorbed dose around
an isotropic point source of radiation in an infinite homogeneous medium (tipi-
cally water) [25]. Many investigators have opted to use these empirical expres-
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sions because they give the dose point-kernel as an analytic function rather than
as tabular data, thus facilitating dose computation. Therefore the dose point-
kernel indicates the mean absorbed dose at a given radial distance per transition,
from an isotropic point source located within a homogeneous, infinite medium.
If one considers the activity within the source region as a three-dimensional grid
of point sources, the absorbed dose at a target point is the convolution of the
contributions from all point sources surrounding this target point.
Quantitative SPECT or PET imaging generally yields activity within voxels (tis-
sue regions with dimensions ranging from a few centimeters to hundreds of mi-
crometers [25]) with a defined volume and shape (cubical or parallelepiped). The
target regions may be defined as the voxels within the image dataset (which may
or may not correspond to source voxels containing activity) or as an independent
set of target points disconnected from the source voxels array. Choosing to dis-
tribute the activity within the whole source voxel volume and to average the dose
across the whole volume of the target voxel, a volume integration over both the
source and the target voxels has to be performed [26].
The popularity of the dose point-kernel 3D-dosimetry approach lies in its speed
of computation compared to Monte Carlo radiation transport. However the con-
volution is a time-consuming mathematical process, expecially for the computers
usually employed in the hospital medical units.
The point-kernel approach can lead to errors in the dose distribution within re-
gions of the body associated with tissue-air or tissue-bone interfaces [26], where
the tissue is non-homogeneous.
Direct Monte Carlo radiation transport:
In recent years the increased computational power of modern computers and
the widespread availability of transport codes increased the use of direct Monte
Carlo transport for 3D-internal dosimetry. Although several Monte Carlo codes
exist that allow the transport of photons and electrons, two codes are particularly
useful for voxel dosimetry applications, primarily due to their ready availability
and continuing developmental support. These are the EGSnrc transport code sys-
tem [27] and the version 5 of the Monte Carlo N-Particles transport code system
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(MCNP5) [28], [25].
The EGS code was originally developed at the Standford Linear Accelerator Cen-
ter for use in computation of electron and photon cascades in high-energy physics.
Due to the increased interest in using EGS within medical physics and internal
dosimetry applications, the transport capabilities of the code have been extended
to low particles energies in the EGS4 version [25]. This code uses a path-segment
model for electron transport, whereas simulation of photon transport is achieved
through conventional Monte Carlo techniques, taking into account the genera-
tion and subsequent transport of all orders of the electron-photon cascade. These
cascades include the generation of secondary and high-order electrons and the
generation of bremsstrahlung photons. In the path-segment model, each electron
track is divided into a certain number of segments and the energy loss in each seg-
ment is sampled from a theoretical energy-loss straggling distribution that takes
into account the combined result of many inelastic collisions. Each segment is fur-
ther divided into two or more sub-segments and the net angular deflection in each
sub-segment is sampled from a theoretical multiple-scattering distribution that
takes into account the combined effect of many elastic collisions [25]. The EGS4
code permits the treatment of multimaterial media during both electron and pho-
ton transport. Consequently, explicit treatment of tissue heterogeneities can be
implemented assigning user-defined tissue compositions to various regions [25].
Since 2011 a highly improved version of EGS4 is available, it is called EGSnrc.
Among the improvements, a completely new electron transport algorithm is used
which removes all known shortcomings of the EGS4/PRESTA algorithm. The
new algorithm allows much larger steps with better accuracy than previously.
A new multiple-scattering theory is used which gets around the shortcomings of
Moliere multiple-scattering theory. It goes from a single-scattering mode for short
steps to a multiple-scattering mode for long steps [27].
The MCNP code was developed at Los Alamos National Laboratory for use in
shielding and weapons design associated with the United States nuclear weapons
program. This code allows the coupled transport of photons and neutrons in user-
defined geometries of arbitrary media. It is a continuous-energy code that uses
interpolation within available cross-sectional data to obtain cross-sectional infor-
mation at all energies that are needed during the transport process. In Version
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4A and 4B, simulations of the electron-photon cascade is allowed [25]. In MCNP5
neutron, photon, electron, or coupled neutron/photon/electron transport can be
simulated. For photons, this version accounts for incoherent and coherent scat-
tering, for the possibility of fluorescent emission after photoelectric absorption,
and for absorption in electron-positron pair production. Electron/positron trans-
port processes account for angular deflection through multiple Coulomb scatter-
ing, collisional energy loss and the production of secondary particles including
X-rays, knock-on and Auger electrons, bremsstrahlung, and annihilation gamma
rays from positron annihilation at rest. Energy ranges are from 1 keV to 1 GeV for
electrons, and from 1 keV to 100 GeV for photons [28]. Both MCNP and EGSnrc
can be installed on Unix workstations and personal computer platforms [25].
Many of the details necessary to implement direct Monte Carlo radiation trans-
port within a radionuclide treatment planning system have been reviewed [29].
This review proposes coupling patient-specific imaging data with EGS5 code to
directly assess three-dimensional distributions of absorbed dose. In this method,
quantitative SPECT or PET images would be used to assign values of cumu-
lated activity to imaging voxels. Next, CT images would be coregistered with
the SPECT or PET voxels, thus a voxel-specific CT number would be used to
assign both an effective atomic number Z and mass density ρ to the tissue in each
voxel. In addiction it is proposed to treat all contiguous voxels having similar Z
as a single medium with variable densities, thus eliminating the need to resample
interaction parameters at every voxel [29].
The direct Monte Carlo calculation must be used when the tissue inhomogeneities
must be considered. It is the only method which can take into account the tissue
inhomogeneities, but it requires much time and calculation-resources, thus, until
now, it can not be applied on a routine basis.
Voxel S-value approach:
The third approach to 3D-internal dosimety calculation applies the MIRD for-
malism to quantitative data on non-uniform distributions of activity within tar-
get regions. Defining a voxel as a small volume element in the target, the MIRD
schema may be applied to assess the average dose absorbed by a given target
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voxel i from n surrounding source voxels h [25]:
di =
n∑
h=1
A˜(h, TD)S(i← h). (3.5)
Where, as explained in section 2, A˜(h, TD) is the number of disintegrations (cumu-
lated activity) that have occurred in the source voxel h over the dose-integration
period TD and S(i ← h) are the S-values at voxel level. The use of PET and
SPECT images enables the in-vivo knowledge of the activity in the single voxel.
The S-values corresponding to the voxel geometry must be provided. Evaluation
of equation 3.5 for all target voxels in the ROI thus enables the calculation of the
DVH within that region.
A voxel S-value is defined as the average dose absorbed by a target voxel per
radioactive decay in a source voxel, under the hypothesis that both target and
source are contained in an infinite homogeneous medium. As a result, the voxel
S-value approach suffers from the same restrictions as the dose point-kernel con-
volution method, because tissue inhomogeneities can not be considered [25].
The voxel S-value approach offers a convenient and rapid tool for 3D-internal
dosimetry calculations similarly to the MIRD approach at the level of whole or-
gan dosimetry (equation 2.6). The use of S-values avoids the need to perform
the CPU-intensive volume integrations required by the dose point-kernel and the
Monte Carlo approachs [25].
The voxel S-values were calculated for soft-tissue cubical voxels of 3 and 6 mm
size using EGS Monte Carlo code for some radionuclides (131I, 99mTc, 90Y , 89Sr,
32P ) and reported in [25]. For each dataset, a cubical array of target voxels region
was established in which a centrally located source voxel was placed. A total array
of 81 × 81 × 81 voxels region was considered. A buffer region was also included
beyond the cubical array of target voxels, to allow for particle backscatter. The
voxel S-value can be expressed as [25]:
S(i← h) = k
∑
j nj Ej φj(i← h,Ej)
Mi
. (3.6)
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Where ni is the number of radiations with energy Ei emitted per nuclear transi-
tion, φ(j ← h,Ei) is the fraction of energy emitted in the source voxel h that is
absorbed by the target voxel j, Mj is the mass of the target voxel (the same for
all the voxel of the same size) and k is a proportionality constant in appropriate
units.
More recently an Italian group calculated voxel S-values for cubical voxels of dif-
ferent sizes and different radionuclides. A free-access database of them can be
found at the web-site: http://www.medphys.it/downloads.htm [30]. In figures
3.4 and 3.5 the S-values published for 3mm, 4.42mm and 6mm cubical voxels
for 131I and 90Y are reported as function of the source-target voxel distance.
As shown in the figure 3.4 the S-values for 131I decreases of ∼ 3 orders of
magnitude at a source-to-taget voxel distance of ∼ 5mm. An effective decrease
in the rate of change of the voxel S-values with increasing distance is evident
beyond ∼ 5mm, where the photon component of the emission spectrum becomes
the only contribute to the S-value (beta-particles deposit their kinetic energy in
the surrounding of the target). For 90Y a decrease of ∼ 5.5 orders of magnitude is
evident at a distance of 12mm from the source voxel. Beyond 12mm the S-values
for 90Y decrease less drastically as bremsstrahlung photons deposit their energy
within voxels further from the source. The non uniform distributions of activity
can be treated within the MIRD schema, provided:
• the activity distribution can be quantitatively measured at voxel level;
• the voxel S-values for the specific radionuclide used and for the proper voxel
dimensions are available.
The voxel S-value approach offers an accurate and computationally efficient tool
to be used within the MIRD schema for an easy calculation of the internal ab-
sorbed dose from non-uniform source distributions within homogeneous media
[25]. Anyway there are not many opportunities to use this algorithm because
voxel S-values are not usable for different radionuclides and/or voxel sizes.
Dosimetry calculations for tissue regions of dimension ranging from few centime-
ters to hundreds of micrometers represent one of the levels of internal dosimetry
of greatest potential for advancing patient-specific dose estimates.
Although having been the object of extensive investigation, voxel dosimetry is not
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Figure 3.4: S-value at voxel level for 131I for 3mm cubical voxels.
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Figure 3.5: S-value at voxel level for 90Y for 3mm cubical voxels.
yet commonly used worldwide; the most important limitations to a wider utiliza-
tion of voxel dosimetry are probably the computational difficulties involved and
the long time needed for calculation.
Among the dosimetric calculation approaches, direct Monte Carlo simulation
is generally considered as the gold standard to account for nonuniform activity
distributions in non-homogeneous media. However, the diffusion of Monte Carlo
internal dosimetry in clinical practice was in part prevented by the inherent com-
plexity and computational demand of the approach [31]. Monte Carlo-based treat-
ment planning systems are not yet commercially available. On the other hand,
electron and photon dose point-kernels have been calculated, mainly in water,
through the various Monte Carlo codes available [32], [33], [34] and approximated
analytical models were proposed in order to simplify the convolution algorithms
[35]. The voxel S-value approach, introduced by the MIRD Committee [25], has
been used more widely than dose point-kernel and direct Monte Carlo compu-
tation approaches, due to its recognized simplicity and reliability [31], [16], [36],
[37].
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Part II
A simple method for the calculation
of 3D internal absorbed dose
distributions without the use of
voxel S-values, point kernels,
or Monte Carlo simulations
The main topic of this work is the development and implementation of a clever
method for the calculation of 3D internal absorbed dose distributions without
the use of voxel S-values, point kernels, or Monte Carlo simulations. The method
presented is straightforward and can be adopted in clinical routine. Moreover the
method presented allows a considerable simplification of the computational oper-
ations with respect to the other available methods, without loosing the accuracy
of the internal absorbed dose calculation at voxel level.
As explained in the section 3.3 the traditional MIRD schema may be applied to
assess the mean absorbed dose to a given target voxel i from n surrounding source
voxels h, including the contribution from the target voxel i itself, as explained in
[25]. The equation which describes the committed absorbed dose at voxel level,
is:
di =
n∑
h=1
A˜(h, TD)S(i← h). (3.5)
This equation enables to calculate the average absorbed dose in each voxel of
the target region. This dose is due to the self-irradiation of the voxel (local de-
position) and to the contribution of the surrounding n voxels. This procedure
enables to define isodose contours and DVHs within the target region.
The 3D voxel dosimetry approach described in the MIRD Pamphlet no.17 [25]
requires the knowledge of the S-values at voxel level for each specific radionuclide
used and for each specific cubical voxel size. While voxel size depends on several
paramenters (reconstruction algorithm, field of view, image size) specific for each
gamma-camera imaging procedure, the S-values reported by the MIRD Pamphlet
No.17 [25] have been calculated only for cubical voxels of 6mm and 3mm size
and for the radionuclides 131I, 99mTc, 90Y , 89Sr, 32P .
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4 Theoretical considerations
According to the traditional MIRD approach, the average target-organ absorbed
dose can be calculated with the following general equation (as explained in section
2.2.1) [7]:
D(rT , TD) = A˜(rT , TD)S(rT ← rT ). (4.1)
Where D(rT , TD) is the average target-organ absorbed dose, S(rT ← rT ) is the
dose coefficient for the target-organ rT irradiating itself, and A˜(rT , TD) is the
time-integrated activity in the same organ. In equation 4.1 the contribution from
other organs to rT is neglected. This is generally considered to be an acceptable
assumption for the β-emitting radionuclides used for therapy (131I, 90Y , 153Sm,
177Lu) [38].
A˜(rT , TD) can be expressed as [6]:
A˜(rT , TD) = A0
∫ TD
0
a(rT , t) dt. (4.2)
Where A0 is the administered activity and a(rT , t) = A(rT , t)/A0 is the time-
related pattern of change in radionuclide concentration, expressed as a fraction
of administered activity (i.e., the kinetics of the radionuclide in the target region
rT ). Under the assumption of a mono-exponential kinetics of the radionuclide in
the target region rT
a(rT , t) = a(rT , 0) e
−λeff t, (4.3)
where a(rT , 0) is the maximum uptake, i.e. the fraction of the administered activ-
ity in the target region rT and λeff is the effective half-life of the radionuclide in
the organ which takes into account of the physical and biological decay constants.
Therefore, if the dose-integration period TD = ∞, it follows that
A˜(rT , TD) =
A0 a(rT , 0)
λeff
, (4.4)
and from equations 4.1 and 4.4 it can be derived that:
D(rT , TD) = S(rT ← rT ) A0 a(rT , 0)
λeff
. (4.5)
Equation 4.5 enables to calculate the average dose D(rT , TD) absorbed by the
macroscopic target-organ rT . If the distribution of the radionuclide is uniform
4. Theoretical considerations
throughout the organ rT , the average dose calculated using equation 4.5 can be
considered as the point-by-point dose (or the absorbed dose at voxel level).
Since the radionuclide activity in an organ rT is linearly related to the raw counts
in the 3D image of the same organ, at voxel level it is:
C(rT , t) =
N∑
i=1
ci(t). (4.6)
Where C(rT , t) is the corrected raw-count value in the whole rT organ, ci(t) is
the corrected raw-count value in the ith-voxel (at the same time t) and N is the
number of voxels in rT . If the radionuclide distribution in rT is uniform, ci(t) has
the same value C(rT , t)/N for all the N voxels.
Based on equations 4.5 and 4.6, the average dose absorbed in the target organ rT
can be written as:
D(rT , TD) = S(rT ← rT ) A0 a(rT , 0)
λeff C(rT , t)
N∑
i=1
ci(t). (4.7)
Since D(rT , TD) is the average absorbed dose in the target region rT , it can be
written also as:
D(rT , TD) =
1
N
N∑
i=1
di. (4.8)
Where di is the absorbed dose in each of the N voxels, i.e. the absorbed dose the
voxel level (eq. 3.5).
From equations 4.7 and 4.8 it follows that:
di = S(rT ← rT ) A0 a(rT , 0)N ci(t)
λeff C(rT , t)
, (4.9)
and based on equations 4.5 and 4.9, the absorbed dose at voxel level can be
written as:
di = D(rT , TD)
N ci(t)
C(rT , t)
. (4.10)
Based on equation 4.10, di can be calculated as a function of the average target-
organ absorbed doseD(rT , TD), scaled taking into account the numberN of voxels
in the target region, the counts ci(t) in the ith-voxel and the whole-target counts
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C(rT , t), under the assumption that the effective decay-constant λeff is the same
for all the voxels [25].
Since all the voxels have the same mass mi = mrT /N (with N number of voxels
in the organ whose mass is mrT ), equation 4.10 can also be written as:
di = D(rT , TD)
mrT
mi
ci(t)
C(rT , t)
. (4.11)
The quations 4.10 and 4.11 can interchangeably be utilized to calculate the ab-
sorbed dose at voxel level di; in particular, they enable to scale the average ab-
sorbed dose D(rT , TD), calculated using the macroscopic S-value, without requir-
ing the S-values at voxel level.D(rT , TD) can be calculated directly using equation
4.5. Equation 4.9, and equations 4.10 and 4.11, are derived from equation 4.8,
that is simply the mathematical definition of the average absorbed dose, without
any additional assumption on local dose deposition and voxel size. Therefore, the
equation 4.9, as well as the consequent equations 4.10 and 4.11, have general
validity.
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5 Comparison between the
simple method and the
MIRD17 voxel S-value approach
5.1 Materials and methods
The application of the new method described by equation 4.10 for calculating
the absorbed dose di at voxel level was tested comparing the di values calculated
using equation 4.10 with those calculated using equation 3.5 [25] for 131I and 90Y ,
referring to cubical voxels of 3mm and 6mm side. Four different situations were
simulated for the comparison developing four different mathematical phantoms
of the target region:
• a homogeneous spherical lesion in which the activity is uniformly distributed;
• a homogeneous spherical lesion in which the distribution of activity changes
from the center to the periphery in discrete declining steps (1− 0.75− 0.5−
0.25);
• a homogeneous spherical lesion in which the distribution of activity changes
from the center to the periphery in discrete, alterning steps (1 − 0.25 −
0.75 − 0.5);
• a homogeneous spherical lesion in which activity is randomly distributed.
These phantoms were built using a software, developed using the open source
GNU-Octave environment (http://www.gnu.org/software/octave/). In figure
5.1 the sections of the spherical phantoms used for the simulation are shown. The
mass of the lesion is 22 g for cubical voxels of 3mm size and 177 g for cubical
voxels of 6mm size, with density 1.04 g/cm3. The administered activity A0 was
1MBq, the whole maximum fraction of administered activity a(rT , 0) in the tar-
get lesion was 8.29× 10−3 and the effective decay constant λeff was 0.006h−1 for
the two radionuclides considered. The number N of 3mm cubical voxels within
the spherical lesion was N = 22/(1.04 ∗ 0.33) = 787 and the same number
was used for the 6mm cubical voxels. The S(rT ← rT ) values for spheres with
1.04 g/cm3 density, for 131I and 90Y , for some different sphere masses are reported
in Table 5.1 (taken from OLINDA/EXM software).
5.1. Materials and methods
Figure 5.1: Sections of the spherical phantoms used for the simulation: 1)
randomly distributed uptake; 2) the uptake changes from the
center to the side in discrete, declining steps (1 - 0.75 - 0.5 -
0.25) normalized to the maximum uptake in the center of the
sphere; 3) the uptake changes from the center to the side in
discrete, alterning steps (1 - 0.25 - 0.75 - 0.5) normalized to
the maximum uptake in the center of the sphere; 4) uniformly
distributed uptake.
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Table 5.1: S values for water spheres (density 1.04 g/cm3) of different
masses, for 131I and 90Y taken from the OLINDA/EXM soft-
ware.
Sphere mass 131I S-values 90Y S-values
(g) (mGy/MBq ∗ h) (mGy/MBq ∗ h)
10 1.17E+001 4.79E+001
20 5.94E+000 2.45E+001
40 3.03E+000 1.25E+001
80 1.56E+000 6.34E+000
100 1.26E+000 5.08E+000
300 4.43E-001 1.73E+000
400 3.39E-001 1.30E+000
500 2.75E-001 1.04E+000
600 2.31E-001 8.71E-001
1000 1.44E-001 5.26E-001
2000 7.63E-002 2.69E-001
3000 5.29E-002 1.80E-001
4000 4.10E-002 1.35E-001
5000 3.34E-002 1.08E-001
6000 2.84E-002 8.96E-002
The S-values for the 22 g and the 177 g (mles) water spheres were calculated
using the following equation:
S(les← les) ' S(ref ← ref) mref
mles
(5.1)
where S(les ← les) is the S-value corresponding to the lesion mass mles and
S(ref ← ref) is the S-value reported in Table 5.1 corresponding to the mass
mref closest to mles. The S(les← les) for the 3mm voxel spheres were obtained
scaling the S(ref ← ref) for a 20 g water-sphere and the S(les ← les) for the
6mm voxel spheres were obtained scaling the S(ref ← ref) for a 100 g water-
sphere. This method to estimate S(rT ← rT ) implies that there is no change in
the sphere energy absorbed fractions for every sphere mass considered. Actually
a new Monte Carlo simulation should be executed for all sphere masses different
from those reported in table 5.1. But except for very small masses (0.1 and 0.5 g),
the equation 5.1 is an acceptable way to calculate the S-values for spheres of differ-
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ent masses, if one uses a value mref as closer as possible to mles. To demonstrate
this we reported in tables 5.2 and 5.3 a comparison between the macroscopic
S-values calculated using the equation 5.1 and those reported in OLINDA/EXM
for spheres of different masses. In figures 5.2 and 5.3 a plot is reported with the
tabulated and the scaled macroscopic S-values, for 131I and for 90Y respectively,
as function of the sphere mass.
In tables 5.2 and 5.3 in the first column, for both the radionuclides considered,
the masses of the spheres are reported; in the second column there are the S-
values calculated using Monte Carlo and reported in OLINDA/EXM (table 5.1);
in the third column there are the S-values calculated using equation 5.1 where
mref is the mass immediately higher than mles and S(ref ← ref) is the S-value
reported in OLINDA/EXM (for example, the S-value for a mass mles of 4 g was
calculated using equation 5.1 considering mref = 6 g; the S-value for a mass mles
of 6 g was calculated using equation 5.1 considering mref = 8 g); in the forth
column there are the differences between the real S-values and those calculated
using equation 5.1. These differences were calculated as 1 − Sscaled/Sreal. Tables
5.2 and 5.3 and figures 5.2 and 5.3 show an acceptable difference (8% maximum
for the unreal lesion of 0.5 g treated with 90Y ) between the real and the scaled
values for both 131I and 90Y .
The MIRD17 method [25] for calculating the absorbed dose at voxel level con-
siders the contribution of the 5 surrounding voxels closest to the target one in
all directions. Therefore the voxel S-values constitute a 11 × 11 × 11 array, at
the center of which there is the voxel S-value for the self irradiation of the target
voxel and in the other positions there are the voxel S-values which account for the
contribution of the surrounding voxels to the dose absorbed by the target one.
This array must be convolved with the lesion-count 3D-array in order to calculate
the dose at voxel level.
To perform the dosimetric convolution calculations of the MIRD17 method a soft-
ware was developed using the open source GNU-Octave environment. The inputs
of the software are the 3D-arrays of the phantoms considered and a file .txt with
the voxel S-values tabulated with respect to the position indices (i, j, k) as shown
in table 5.4.
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Figure 5.2: S-values for water spheres (density 1.04 g/cm3) vs sphere
mass for 131I. The blue points are the S-values reported in
the OLINDA/EXM software, while the red points are the
S-values obtained using equation 5.1. A ± 6% uncertainty is
considered [16].
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Figure 5.3: S-values for water spheres (density 1.04 g/cm3) vs sphere
mass for 90Y . The blue points are the S-values reported in
the OLINDA/EXM software, while the red points are the
S-values obtained using equation 5.1. A ± 6% uncertainty is
considered [16].
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Table 5.2: S-values for water spheres (density 1.04 g/cm3) of different
masses, for 131I. In the second column there are the S-values
reported in the OLINDA/EXM software, in the third column
those calculated using equation 5.1 and in the fourth column
the differences between the real S-values and those calculated
using equation 5.1.
131I
Sphere mass Real S-values Scaled S-values Differences
(g) (mGy/MBq ∗ h) (mGy/MBq ∗ h)
0.1 1.04E+003 1.07E+003 -0.03
0.5 2.14E+002 2.22E+002 -0.04
1 1.11E+002 1.12E+002 -0.01
2 5.62E+001 5.70E+001 -0.01
4 2.85E+001 2.88E+001 -0.01
6 1.92E+001 1.93E+001 -0.01
8 1.45E+001 1.46E+001 -0.01
10 1.17E+001 1.19E+001 -0.02
20 5.94E+000 6.06E+000 -0.02
40 3.03E+000 3.12E+000 -0.03
80 1.56E+000 1.58E+000 -0.01
100 1.26E+000 1.33E+000 -0.05
300 4.43E-001 4.52E-001 -0.02
400 3.39E-001 3.44E-001 -0.01
500 2.75E-001 2.77E-001 -0.01
600 2.31E-001 2.40E-001 -0.04
1000 1.44E-001 1.53E-001 -0.06
2000 7.63E-002 7.94E-002 -0.04
3000 5.29E-002 5.47E-002 -0.03
4000 4.10E-002 4.18E-002 -0.02
5000 3.34E-002 3.341E-002 -0.02
6000 2.84E-002
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Table 5.3: S-values for water spheres (density 1.04 g/cm3) of different
masses, for 90Y . In the second column there are the S-values
reported in the OLINDA/EXM software, in the third column
those calculated using equation 5.1 and in the fourth column
the differences between the real S-values and those calculated
using equation 5.1.
90Y
Sphere mass Real S-values Scaled S-values Differences
(g) (mGy/MBq ∗ h) (mGy/MBq ∗ h)
0.1 2.82E+003 3.80E+003 -0.35
0.5 7.60E+002 8.20E+002 -0.08
1 4.10E+002 4.36E+002 -0.06
2 2.18E+002 2.28E+002 -0.05
4 1.14E+002 1.16E+002 -0.02
6 7.78E+001 7.87E+001 -0.01
8 5.90E+001 5.99E+001 -0.01
10 4.79E+001 4.90E+001 -0.02
20 2.45E+001 2.50E+001 -0.02
40 1.25E+001 1.27E+001 -0.03
80 6.34E+000 6.35E+000 -0.00
100 5.08E+000 5.19E+000 -0.02
300 1.73E+000 1.73E+000 -0.00
400 1.30E+000 1.30E+000 -0.00
500 1.04E+000 1.05E+000 -0.01
600 8.71E-001 8.77E-001 -0.01
1000 5.26E-001 5.38E-001 -0.02
2000 2.69E-001 2.70E-001 -0.00
3000 1.80E-001 1.80E-001 -0.00
4000 1.35E-001 1.35E-001 -0.00
5000 1.08E-001 1.08E-001 -0.00
6000 8.96E-002
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Table 5.4: Some voxel S-values (mGy/MBq∗h) for 131I for cubical voxels
of 3mm side.
131I, 3mm voxel size
i j k voxel S-value
(mGy/MBq ∗ s)
0 0 0 8.99E-01
0 0 1 3.02E-02
0 0 2 4.65E-04
0 0 3 2.04E-04
0 0 4 1.13E-04
0 0 5 7.23E-05
0 1 0 3.02E-02
0 1 1 2.41E-03
0 1 2 3.71E-04
0 1 3 1.83E-04
0 1 4 1.07E-04
0 1 5 6.94E-05
0 2 0 4.65E-04
0 2 1 3.71E-04
0 2 2 2.30E-04
0 2 3 1.40E-04
0 2 4 9.06E-05
0 2 5 6.24E-05
The program reads the file and reconstructs the voxel S-value 3D-array. Than
it calculates the dose at the voxel level di according to the MIRD17 method [25].
In addiction this program performs dosimetric calculations at voxel level using
the equation 4.10 and calculates the local deposition, i.e. the absorbed dose cal-
culated in each voxel without considering the contribution of the surrounding
voxels. Therefore it requires as input the macroscopic S-value for the lesion mass
considered (simple method, equation 4.10), and the voxel S-value S(0, 0, 0) (cal-
culation of the absorbed dose due to local deposition: 3.236Gy/MBq ∗ h for 131I
and 5.724Gy/MBq ∗ h for 90Y for 3mm voxel size; 0.45Gy/MBq ∗ h for 131I
and 1.231Gy/MBq ∗ h for 90Y for 6mm voxel size). The software returns a fig-
ure divided in four areas, one for each phantom considered. In each of them the
DVHs calculated with the two methods and the DVH for the local dose depo-
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sition are shown. This figure has been obtained for the two voxel sizes and for
the two radionuclides considered. The software also measures the elapsed time
for calculating the dose at voxel level using equation 3.5 [25] and using equation
4.10.
5.2 Calculation of statistical uncertainties
The uncertainty affecting the absorbed dose at voxel level evaluated using equa-
tions 3.5 and 4.10 was calculated considering the main sources of uncertainties:
• to determine the time-dependent cumulated activity in the desired source
regions, serial measurements of activity must be made afterwards adminis-
tration of the radiopharmaceutical. These can be performed using quanti-
tative imaging techniques including planar scintillation-camera, SPECT or
PET. The resulting time-activity curve obtained for each source region can
be analyzed to provide A˜(rS, TD) as described in section 2.3.
Under the assumption of a mono-exponential kinetics of the radionuclide
in the target region rT , the quantities required for determining A˜(rS, TD)
are: the administered activity A0, the maximum uptake a(rT , 0), i.e. the
fraction of the administered activity in the target region rT and the effec-
tive half-life λeff . The administered activity A0 in the target region rT was
measured with a dose calibrator. Therefore, the accuracy of the measure
depends on the accuracy of the instrument. A ± 10% uncertainty was as-
sumed. The maximum uptake a(rT , 0) in the target region was measured
comparing the patient’s SPECT images to those of a uniform phantom with
a known activity concentration. The factor needed to convert the SPECT
counts per voxel to this known concentration is the calibration factor and
can be used for other SPECT images acquired using the same setup and
the same reconstruction method. Hence, uncertainty on a(rT , 0) depends
on the measurement of the phantom’s activity concentration (for which we
consider a ± 3% uncertainty), and on the statistical error in the patient’s
images used. An overall uncertainty of ± 9% was considered for a(rT , 0).
The effective half-life takes into account of the physical and biological de-
cay constants. The ucertainty on the physical decay constant is low and
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mostly negligible in comparison with uncertainties in the other terms. The
uncertainty on the biological decay constant depends on the measurements
of activity made afterwards administration of the radiopharmaceutical. Un-
certainty in estimates of the parameter λeff may be introduced as a result
of improper sample timing and an inadequate number of samples when ana-
lytical functions are used to approximate the measured time-activity curve.
If an adequate number of samples is acquired and a proper simple timing is
choosed the ucertainty on the biological decay constant is low and mostly
negligible in comparison with uncertainties in the other terms.
• image-derived counts are used both in equation 4.9 and 3.5. These counts
have been obtained using a SPECT, which needs attenuation, scatter and
partial volume effect compensations to produce accurate images. The atten-
uation compensation requires a high quality map of the attenuation coeffi-
cients for each voxel in the image. This map should have a resolution on the
order of the image resolution and be well-registered to the SPECT image.
Modern SPECT/CT systems generally provide well-registered attenuation
maps. The noise level and the resolution in CT-derived images is such that
they are more than adequate as attenuation maps. One limitation is that
motions can have different effects on the CT images than on the SPECT
images. With well-registered CT-based attenuation maps, the attenuation
compensation is effective and produces accurate images [39]. The scatter
compensation methods account for scatter using energy- or spatial-based
estimates. The scatter estimate is often subtracted from the measured data
[39]. Partial volume compensation involves the use of recovery coefficients,
which are the fraction of the true activity in an object that is recovered in the
estimate. Post-reconstruction-based methods estimate the recovery factors
for the specific object modeling the effects of the resolution on the estimated
activities. Partial volume corrections must be performed when quantifying
the activity within objects of sizes lower than twice of the FWHM spatial
resolution of the imaging system [39].
The uncertainty on the counts from the SPECT compensated images was
considered. A Poissonian statistic cannot be assumed. Thus, a SPECT im-
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age of a uniform activity phantom was acquired. Analysis of these data
showed a small influence of this uncertainty on the dose calculation (∼ 1%);
• to determine the uncertainty on the S-values we based on the recent paper
of Pacilio et al. [16], who compared the S-values calculated using differ-
ent Monte Carlo (MC) codes (MCNP4C, EGSnrc and GEANT4) to those
calculated using EGS4 and published in the MIRD Pamphlet No.17 [25]
and analyzed their impact on absorbed dose evaluations. Consistent dif-
ferencies were found between voxel S-values calculated with the MC codes
employed and those published in the MIRD Pamphlet No.17. For 90Y , for
3mm voxel-size the differences range from −50% to −90% considering S-
values referred to voxels at a distance ranging from 10 to 13mm from the
target one. For 6mm voxel-size the differences range from −50% to −90%
considering S-values referred to voxels at a distance ranging from 10 to
17mm from the target one. For 131I, for 3mm voxel-size the differences
range from −31% to −24% considering S-values referred to voxels at a dis-
tance of 4mm from the target one and range from −20% to 20% for larger
distances. For 6mm voxel-size the differences reach −22% considering S-
values referred to voxels at a distance of 6mm from the target one and range
from −10% to 3% for distances larger than 10mm. These differences may
be partially attributed to the different models for electron transport and
multiple scattering theories. Larger divergences are in the Bremsstrahlung
region. Despite the big differences in the voxel S-values, observed at large
distaces from the target voxel, the impact of these differencies on the ab-
sorbed dose is limited: for 90Y and for 3mm voxel size spheres of different
masses, depending on the MC codes employed, the differences in absorbed
dose range between −4% and 2%; for 131I and for 3mm voxel size spheres
of different masses, depending on the MC codes employed, the differences in
absorbed dose range between −9% and −3%. The impact of the differences
between the voxel S-values on dose calculation is strongly dependent on the
distance at which the S-values refer. At large distance from the target voxel,
the voxel S-value is several order of magnitude lower than the voxel S-value
for self irradiation, so its contribution to the absorbed dose is negligible.
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More consistent differences in the absorbed dose have been evidenced for
131I. The lower energy contributions to the beta spectrum, togheter with
the differences in modeling low-energy electron transport among the MC
codes, generate stronger differences in the voxel S-values for self irradiation
and for the first neighbour voxels, affecting more significantly the dose cal-
culation. Considering the results published by Pacilio et al. [16] we asses
for 131I an uncertainty contribution of ± 6% and for 90Y an uncertainty
contribution of ± 3% for dose calculations using the MIRD17 method [25].
For the simple method we considered that the uncertainty on the absorbed
dose evaluations, due to the uncertainty on the macroscopic S-values, was
of the same order than that due to voxel S-values for the MIRD17 method,
hence we asses for 131I and for 90Y an uncertainty contribution of ± 6% in
the dose calculation.
Once all the uncertainties in the dose calculation have been identified, they can
be summed-up in quadrature. An overall uncertainty on the absorbed dose at
voxel level of about ± 20% has been considered for both the methods consistently
with the literature [40], [17].
5.3 Results
Figures 5.4 and 5.5 show the differential dose volume histograms calculated us-
ing equations 3.5 and 4.10 for 131I and 90Y respectively, for 3mm voxel size,
in the four situations described. Results of the same calculation for 6mm voxel
size are reported in figures 5.6 and 5.7. Figures 5.8 and 5.9 show the integral
dose-volume histograms calculated with the two different methods for 131I and
90Y respectively, for 3mm voxel size, in the four situations described. Results of
the same calculation for 6mm voxel size are reported in figures 5.10 and 5.11.
The blue line (indicated as ”MIRD17method”) represents the results of the cal-
culation performed via the standard voxel dosimetry approach [25], while the
red line (indicated as ”Simplemethod”) represents the results of the calculation
performed using the proposed simple method. The gray area corresponds to the
uncertainty (± 20%) associated to the MIRD17 method. The area corresponding
to the uncertainty affecting the simple method (not plotted in the figure for the
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sake of clarity) is of the same order of magnitude as for the MIRD17 method.
The green line corresponds to the local deposition, i.e. absorbed dose calculated
in each voxel without considering the contribution of the surrounding voxels.
The DVHs obtained for 131I and 90Y using equations 3.5 and 4.10 for the cal-
culation are in agreement for all the four situations described. Some discordance
between the DVHs calculated with the two methods is observed in the case of the
uniform phantom for both radionuclides and both voxel sizes. This difference is
due to the S-values used. The macroscopic S-values reported in OLINDA/EXM
software were calculated using an energy absorbed fraction less than, but close to
1, while the S-values at voxel level were calculated using a lower energy absorbed
fraction. This is because in a small voxel (3mm size for example), the number
of particles escaping from that voxel will be relatively high compared to that es-
caping from a bigger sphere. This means that AFvoxel < AFsphere, where AFvoxel
is the energy absorbed fraction for a small voxel and AFsphere is the energy ab-
sorbed fraction for a macroscopic sphere. This difference increases as the mass
of the target considered decreases, beacause the energy absorbed fraction for the
macroscopic S-value should be proportionally lower as the target mass decreases,
but this is not the case. Consequently, agreement between the new method and
the standard MIRD17 method [25] improves as the target increases in size (com-
pare figures 5.4, 5.5, 5.8 and 5.9, with target region mass 22 g, with figures 5.6,
5.7, 5.10 and 5.11, with target region mass 177 g).
Moreover the difference between the energy absorbed fractions is lower for the ra-
dionuclides emitting lower energy beta particles. The maximum energy of the 131I
emitted beta particles is 606 keV , while for those emitted by 90Y is 2.27MeV .
Therefore the energy absorbed fraction for S-values for voxels of the same size
is higer for 131I than for 90Y (AF131I > AF90Y ). As a consequence agreement
between the new method and the standard MIRD17 method is better for 131I
(compare figures 5.4, 5.6, 5.8 and 5.10 for 131I, with figures 5.5, 5.7, 5.9 and 5.11
for 90Y ).
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Figure 5.4: Differential dose-volume histograms calculated using equa-
tion 3.5 [25] (the blue line), equation 4.10 (the red line) and
considering only the local deposition (the green line) for 131I
in four different situations. The target is a 22 g water-sphere
with 3mm voxel size.
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Figure 5.5: Differential dose-volume histograms calculated using equa-
tion 3.5 [25] (the blue line), equation 4.10 (the red line) and
considering only the local deposition (the green line) for 90Y
in four different situations. The target is a 22 g water-sphere
with 3mm voxel size.
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Figure 5.6: Differential dose-volume histograms calculated using equa-
tion 3.5 [25] (the blue line), equation 4.10 (the red line) and
considering only the local deposition (the green line) for 131I
in four different situations. The target is a 177 g water-sphere
with 6mm voxel size.
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Figure 5.7: Differential dose-volume histograms calculated using equa-
tion 3.5 [25] (the blue line), equation 4.10 (the red line) and
considering only the local deposition (the green line) for 90Y
in four different situations. The target is a 177 g water-sphere
with 6mm voxel size.
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Figure 5.8: Integral dose-volume histograms calculated using equation
3.5 [25] (the blue line), equation 4.10 (the red line) and con-
sidering only the local deposition (the green line) for 131I
in four different situations. The target is a 22 g water-sphere
with 3mm voxel size. The gray area corresponds to the un-
certainty (± 20%) associated to the MIRD17 method. The
area corresponding to the uncertainty affecting the simple
method (not plotted in the figure for the sake of clarity) is
of the same order of magnitude as for the MIRD17 method.
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Figure 5.9: Integral dose-volume histograms calculated using equation
3.5 [25] (the blue line), equation 4.10 (the red line) and con-
sidering only the local deposition (the green line) for 90Y in
four different situations. The target is a 22 g water-sphere
with 3mm voxel size. The gray area corresponds to the un-
certainty (± 20%) associated to the MIRD17 method. The
area corresponding to the uncertainty affecting the simple
method (not plotted in the figure for the sake of clarity) is
of the same order of magnitude as for the MIRD17 method.
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Figure 5.10: Integral dose-volume histograms calculated using equation
3.5 [25] (the blue line), equation 4.10 (the red line) and con-
sidering only the local deposition (the green line) for 131I in
four different situations. The target is a 177 g water-sphere
with 6mm voxel size. The gray area corresponds to the un-
certainty (± 20%) associated to the MIRD17 method. The
area corresponding to the uncertainty affecting the simple
method (not plotted in the figure for the sake of clarity) is
of the same order of magnitude as for the MIRD17 method.
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Figure 5.11: Integral dose-volume histograms calculated using equation
3.5 [25] (the blue line), equation 4.10 (the red line) and con-
sidering only the local deposition (the green line) for 90Y in
four different situations. The target is a 177 g water-sphere
with 6mm voxel size. The gray area corresponds to the un-
certainty (± 20%) associated to the MIRD17 method. The
area corresponding to the uncertainty affecting the simple
method (not plotted in the figure for the sake of clarity) is
of the same order of magnitude as for the MIRD17 method.
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Another cause of the difference between the DVHs calculated with equation 3.5
and the DVHs calculated with equation 4.10 is the number of boundary voxels
compared to the whole number of voxels in the phantoms. The absorbed dose
in a voxel i can be calculated using the two methods. In equation 3.5 [25] the
contribution of the surrounding voxels to the target one is considered; in equation
4.10 the average absorbed dose in the whole phantom is scaled taking into account
only the counts in the ith-voxel. If the voxel i is inside the sphere volume the
two methods are almost equivalent but, if the voxel i is on the spherical surface,
the dose absorbed in that voxel calculated with equation 3.5 will be lower than
the dose calculated with equation 4.10. This is because equation 3.5 considers the
contribution of the voxels outside the sphere surrounding the ith-voxel, but this
contribution is null, while equation 4.10 considers only the counts in the ith-voxel
and thus does not consider the dose contribution from voxels outside the spherical
volume. Moreover, as explained before, AFvoxel < AFsphere. To better explain this
concept, consider a boundary voxel in which the counts ci are the same as in an
inner voxel. Calculating the absorbed dose in the boundary voxel with equation
4.10, it will be the same as that absorbed in the inner voxel, because the counts
are the same; however, calculating the absorbed dose in the boundary voxel with
equation 3.5, it will be lower than the absorbed dose in the inner voxel, because
the contribution of the outer voxels is null. For this reason if the percentage of
the boundary voxels is lower, i.e. higher volume phantoms, the two methods are
in better agreement. This is illustrated in figure 5.12. Here two situations are
considered: an homogeneous spherical 90Y contaminated water phantom (3mm
voxel size) whose mass is 7 g and an homogeneous spherical 90Y contaminated
water phantom (3mm voxel size as for the previous phantom) whose mass is
575 g. The dose calculated using the MIRD17 method [25] is lower than that
calculated using the simple method in the 55% of the volume for the smaller
phantom; while this percentage is reduced to 20% for the bigger phantom. This
is due to the higher fraction of boundary voxels in the smaller phantom.
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Figure 5.12: Integral dose-volume histograms calculated using equation
3.5 [25] (the blue line), equation 4.10 (the red line) and
considering only the local deposition (the green line) for
90Y . The target is a 7 g water-sphere (above) and a 575 g
water-sphere (below) with 3mm voxel size. The horizontal
lines indicate the percentage of inner voxels (45% above
and 80% below) and boundary voxels (55% above and 20%
below) with respect to the total number of voxels in the
target.
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Figures 5.5, 5.7, 5.9 and 5.11 show that agreement between the DVHs calcu-
lated for 90Y for the random phantom using equations 3.5 and 4.10 is poorer. This
is probably due to all the reasons explained before. An high fraction of boundary
voxels compared to the total number of voxels in the phantom results in poorer
agreement between the DVHs obtained using MIRD17 method [25] and the sim-
ple method.
In addiction the results obtained for the unrealistic random phantom constitute
the worst possible case in terms of agreement between the two calculation meth-
ods. In this case there are very different activity levels distributed randomly
throughout the target. This is an unrealistic situation. The 90Y contaminated
random phantom with 3mm voxels size, used previously, was convolved with a
gaussian 3D array with standard deviation σ = 5.1mm (FWHM= 12mm),
corresponding to a reasonable point spread function for a SPECT, and of 6σ di-
mensions. In this realistic situation, represented in figure 5.13, there is agreement
between the DVHs calculated using the MIRD 17 method [25] (equation 3.5) and
the simple method 4.10.
The measurements of the elapsed time for the calculation of the 3D dose dis-
tribution proved that the new and simple method is faster than the MIRD17 [25]
method. For each of the spherical phantom considered (787 voxels) the 3D dose
calculation using equation 3.5 used 247 ± 3s, while the 3D dose calculation using
equation 4.10 used 44 ± 4 × 10−6s.
5.4 Discussion
The aim of this work is to demonstrate that it is possible to obtain an acceptable
estimate of 3D voxel dosimetry using the new method described in equation 4.10,
that overcomes the need of calculating and using the S-values at voxel level. This
result can be achieved scaling the average target absorbed dose D(rT , TD), which
can be calculated using dedicated tools as OLINDA/EXM, under the assumptions
of a monoexponential radionuclide kinetics and of the same effective half-life of
the radionuclide in all the voxels of the target region. These assumptions, crucial
for the validity of the method presented, are considered valid and have been used
in many studies [25], [41].
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Figure 5.13: Differential (above) and integral (below) dose-volume his-
tograms calculated using equation 3.5 [25] (the blue line),
equation 4.10 (the red line) and considering only the lo-
cal deposition (the green line) for 90Y . The target is a
22 g water-sphere with 3mm voxel size, where the activity
is randomly distributed and filtered with a gaussian with
σ = 5.1mm. The gray area corresponds to the uncertainty
(± 20%) associated to the MIRD17 method. The area cor-
responding to the uncertainty affecting the simple method
(not plotted in the figure for the sake of clarity) is of the
same order of magnitude as for the MIRD17 method.
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The intrinsic limitations of the standard MIRD17 approach [25] (limited num-
ber of voxel sizes, limited number of radionuclides) have been overcome by two
recent articles. In the first one [36], a new method for generating voxel S-values
at any user-defined voxel dimension is presented. This method is based on a re-
sampling algorithm used to produce voxel S-values from a set of voxel S-values
generated at a fine spatial resoultion. This method enables one to overcome the
need for fixed voxel size (3mm and 6mm) calculated S-values, as reported in
MIRD Pamphlet No. 17 [25]. In the second article [30] the authors calculated
the voxel S-values for a certain number of voxel sizes and radionuclides (available
on-line at http://www.medphys.it/down_svoxel.html).
However the new and straightforward method provides an effective alternative to
overcome the limitation of the voxel S-value MIRD approach. The main adavn-
tages of the new method are that it can be applied irrespective of the voxel size
and it allows to avoid time-consuming CPU-intensive calculations because it is
very fast. Medical physicians may utilize the DVHs and isodose curves obtained
in optimizing radionuclide therapy.
The method described by equation 4.10 does not consider exclusive local depo-
sition of the dose (i.e., assuming no contribution form the surrounding voxels to
the target one). This is well illustrated in figures 5.8, 5.9, 5.10 and 5.11, where
the DVHs of the local deposition are sistematically and considerably lower than
the others.
The agreement between the dose calculations performed using the MIRD17 and
the new method (equations 3.5 and 4.10) is due to the fact that equation 4.10
derives from the mathematical definition of the average absorbed dose (equation
4.8), without any hypothesis (except the mono-exponential kinetics and the same
half-life of the radionuclide in all the voxels of the target region); in particular, the
S(rT ← rT ) macroscopic S-values used in equation 4.10 includes the cross-dose
components.
The macroscopic S-values for the various organs (of different densities) and for
various radionuclides are available on-line at the web-site:
http://doseinfo-radar.com,
as well as in the OLINDA/EXM software. These S-values are usually employed
worldwide for dosimetric estimates of the whole target/organ, without consider-
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ing non-uniform activity distribution. Using these macroscopic S-values calculated
taking into account the real density of the organs considered, the new method
overcomes the problems due to the different densities of the organs.
The new method requires the use of other macroscopic parameters, such as
a(rT , 0) (the maximum fraction of administered activity in the whole organ),
λeff (the effective half-life of the radionuclide in the whole organ) andMrT (mass
of the whole organ) usually employed in the well-established calculation of the
average absorbed dose to the whole tissue/organ, while N , ci(t) and C(rT , t) can
be obtained from the SPECT/CT (or PET/CT) 3D images.
The new method has general validity and can be applied not only for 131I and 90Y ,
but also for other radionuclides used in therapy, moreover it allows to estimate
the absorbed dose at voxel level in non-uniform radiopharmaceutical distributions
without requiring CPU-intensive calculations.
61
6 Practical application of the
simple method
The agreement between the dose calculations performed using the new and the
standard MIRD 17 [25] methods was tested in four practical situations. The
3D dosimetry was performed for four patients treated using 90Y -bearing micro-
spheres for the hepatocellular carcinoma (HCC) therapy.
The liver may be the locus of various primary neoplasms. Hepatocellular carci-
noma is the visceral malignancy with the highest and increasing annual incidence
worldwide [42]. The median survival is less than 1 year [42] and most of those
affected by hepatocellular carcinoma die either from cirrhosis or from local tumor
progression. Surgical resection and transplantation produce reasonable 5 year sur-
vival rates; however, fewer than 10% of those in whom hepatocellular carcinoma
is diagnosed are candidates for either of these procedures. There is a need for
more effective treatments of this disease in these patients [42].
Because the liver may be both a transit point for metastasis and the location of
substantial tumor burden, effective hepatic control of cancer may favorably alter
the overall progression of the disease. Recently the transarterial administration
of 90Y micro-spheres for liver-directed cancer therapy has been proposed. The re-
sults of numerous studies have supported the use and confirmed the effectiveness
of 90Y -bearing micro-spheres in the treatment of hepatic primary neoplasms [43],
[44], [45], [46], [47] and metastatic neoplasms [48], [49], [50].
90Y -bearing micro-spheres are point sources of radiation that preferentially local-
ize in the peritumoral and intratumoral arterial vasculature [52]. This characteris-
tic makes them suitable vehicles for selective delivery of very high radiation doses
to tumors while radiation exposure to the normal hepatic parenchyma remains
within tolerable limits. There are currently two commercially available micro-
sphere devices in which 90Y is incorporated: one with microspheres made of glass
(Thera-Sphere; MDS Nordion, Ottawa, Ontario, Canada) and the other with mi-
crospheres made of resin (SIR-Spheres; Sirtex Medical, Sydney, Australia). Every
sphere is characterized by the same activity concentration [42] (figure 6.1).
The theraputic intra-arterial injection of the 90Y micro-spheres is preceded by
a pre-therapeutic phase. The aim of pre-therapeutic assessment of the hepatic
arterial vasculature is to ensure delivery of the micro-spheres to the target [42].
During the pre-therapeutic phase the tumor is localized, its volume (and mass) is
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Figure 6.1: Left: photomicrograph (original magnification, ×200) shows
glass microspheres; Right: photomicrograph (original magni-
fication, ×1000) shows resin microspheres.
measured using specific CT images with contrast, the hepatic vessels which pro-
vide blood supply to the tumor are studied using arteriographic-images and each
of them except one (considered the best seat for the microspheres infusion) is em-
bolized by an interventional-radiology procedure. After the selective embolization
of the blood vessels, the patient is injected with 99mTc-labeled macroaggregated
human albumin which remain blocked in the arterioles which vascularize the le-
sion. A SPECT/CT is acquired in order to check the distribution of the activity
in the tumor and other critical organs (lungs, kidneys, healthy part of the liver).
Based on the activity distribution in the target the medical physicist performs
the dosimetry and calculates the appropriate activity to be administered to the
patient according to the nuclear medicine specialist prescriptions.
Infusion is performed in an angiography suite, primarily by an interventional
radiologist, with the 90Y micro-spheres activity previously prepared [42]. Once
injected the radionuclide will decay in the target and the spheres will remain in
the tissue.
For this kind of therapy the hypothesis of monoexponential radionuclide kinetics
and of the same effective half-life of the radionuclide in all the voxels of the target
region can be used. The contribution of the other organs/tissues to the absorbed
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dose in the lesion can be neglected, similarly for the biological clearance, because
the radionuclide is trapped in the tumor arterioles. In this case the radionuclide
capture is a mechanical (not a metabolic) process, and the effective half-life of
the radionuclide in the lesion is exactly the physical half-life of the radionuclide
(λeff = 0.010817h−1). The maximum fraction of administered activity a(rT , 0)
can be considered to be 1.
The calculation of the absorbed dose at voxel level di was performed using the
SPECT/CT images of 99mTc-labeled macroaggregated human albumin. Thus the
implicit assumption that the 90Y micro-spheres will distribute in the tissue in the
same way as the macroaggregated human albumin marked with 99mTc is done.
The tumor Volume of Interest (VOI) must be identified on the SPECT/CT im-
ages. The tumor can be identified only on the CT images with contrast, thus it
is necessary to mach this image (performed before the enrollment of the patient)
with the CT performed during the SPECT-CT scan. Therefore, the CT image
with contrast was aligned with the CT image well-registered with the SPECT im-
age using the open source software ImageJ and in particular the AlignStack3TP
plugin
(http://www.med.harvard.edu/jpnm/ij/plugins/Align3TP.html).
We saved the aligned CT image as a dicom image using the DicomImportExport
plugin (http://www.iftm.de/telemedizin/dcmimex.htm).
In order to select the VOI on the SPECT image we used the open source
software AMIDE (http://amide.sourceforge.net/) which allows to select a
free-hand drawn VOI and to save the counts in each voxel and the respective
position on a .tsv file (figure 6.2). The VOI identified on the CT images, was
transported on the functional SPECT one, in order to consider the distribution
of the activity in the lesion (figure 6.3). Therefore the 3D array with the counts
ci in each voxel of the target region and the whole-lesion counts C(rT , t) were
obtained.
A software was created using GNU-Octave which requires as input a file.txt
with the SPECT counts, reads that file and reconstructs the selected volume.
The software also requires as input the file.txt with the voxel S-values for cubical
voxels of 4.42mm side, which is the SPECT voxel dimension, tabulated with re-
spect to the position indices (i, j, k). It reads this file and reconstructs the voxel
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Figure 6.2: Amide screen with a CT slice on which a VOI has been free-
hand drown.
Figure 6.3: Amide screen with a SPECT slice on which a VOI has been
transported from the CT images.
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S-values array, so it calculates the dose at voxel level di according to the standard
MIRD17 method [25] performing the convolution between this array and the le-
sion array. In addiction this program performs dosimetric calculations using the
new, simple method. The macroscopic S-value corresponding to the real mass of
the target was calculated using equation 5.1. The value of mles was calculated
using the number of voxels in the selected VOI ((4.42mm)3 voxel volume) and
the density 1.04 g/cm3. Moreover the software performs dosimetric calculations
of the absorbed dose due to the local deposition, i.e. the absorbed dose calculated
in each voxel without considering the contribution of the surrounding voxels. The
software also measures the elapsed time for calculating the dose at voxel level
using equation 3.5 [25] and using equation 4.10.
Table 6.1:
Lesion mass Elapsed time Elapsed time
(g) MIRD method (s) simple method (s)
59 321 ± 7 62 ± 1×10−6
343 2136 ± 12 13 ± 3×10−5
377 2284 ± 12 13 ± 3×10−5
1073 3830 ± 90 35 ± 4×10−5
The program returns the DVHs calculated with the two methods and for the
local dose deposition. DVHs obtained for all the four patients considered are
reported in figures 6.4, 6.5. The DVHs obtained using equations 3.5 and 4.10 are
in good agreement for all the four patients. In table 6.1 the elapsed times for
calculating the absorbed dose at voxel level using equations 3.5 and 4.10 for the
four patients are shown. The elapsed time for the calculation using the standard
MIRD method strongly depends on the number of voxels in the lesion varying
from 321 s for a 59 g lesion, to 3830 s for a 1073 g lesion.
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Figure 6.4: Integral dose-volume histograms calculated using equation
3.5 (the blue line), equation 4.9 (the red line) and con-
sidering only the local deposition (the green line) for 90Y
with 4.42mm voxel size. The target is a 1073 g above and
377 g below hepatic lesion treated with administered activ-
ity A0 = 4076MBq and A0 = 1140MBq respectively. The
gray area corresponds to the uncertainty (± 20%) associated
to the standard MIRD17 method. The area corresponding to
the uncertainty affecting the simple method (not plotted in
the figure for the sake of clarity) is of the same order of
magnitude as for the MIRD17 method.
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Figure 6.5: Integral dose-volume histograms calculated using equation
3.5 (the blue line), equation 4.9 (the red line) and con-
sidering only the local deposition (the green line) for 90Y
with 4.42mm voxel-size. The target is a 343 g above and
59 g below hepatic cancer treated with administered activ-
ity A0 = 3094MBq and A0 = 2419MBq respectively. The
gray area corresponds to the uncertainty (± 20%) associated
to the standard MIRD17 method. The area corresponding to
the uncertainty affecting the simple method (not plotted in
the figure for the sake of clarity) is of the same order of
magnitude as for the MIRD17 method.
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7 Conclusions
Dosimetric approaches that take into account the possible non-uniform activ-
ity distribution within the target and critical organs are becoming increasingly
essential for obtaining dosimetric estimates when performing therapy with radio-
pharmaceuticals. The possibility to define a DVH for the lesion and for the critical
organs is crucial for predicting the probability of tumor control as well as the ef-
fect of radiations on the surrounding non-target tissue (as currently achieved in
external beam therapy).
Provided that some factors (attenuation correction, spatial resolution, reconstruc-
tion algorithms) are adequately taken into account, 3D SPECT and PET images
can yield reliable estimates of local activity concentrations. Although outside the
scope of this work, it should be emphasized that understanding and managing
these factors is crucial to ensure reliable quantitative data, since PET and SPECT
images do not represent the true distribution of activity [39].
The voxel S-value approach, introduced by the MIRD Committee [25], has been
used more widely than dose point-kernel and direct Monte Carlo computation
approaches, due to its recognized simplicity and reliability [31], [16], [36], [37].
The aim of this work is to demonstrate that it is possible to obtain an acceptable
estimate of the 3D dose distribution using the new and straightforward method
described by equation 4.10, which overcomes the necessity of calculating and using
the S-values at voxel level. This result can be achieved scalging the average tar-
get absorbed dose D(rT , TD) (which can be calculated also using dedicated tools
as OLINDA/EXM software [15]), under the assumptions of a monoexponential
radionuclide kinetics and of the same effective half-life λeff of the radionuclide
in all the voxels of the target region. This assumptions, essential for the validity
of the new method, are considered valid and has been used in many studies [25],
[41].
The clever and straightforward method presented here provides an effective al-
ternative to overcome the limitation of the voxel S-value MIRD approach [25]
(target density, limited number of voxel sizes, limited number of radionuclides).
The main adavntages of the new method for estimating the 3D absorbed dose
distribution are:
• it can be applied irrespective of the voxel size;
• it has general validity and can be applied not only for 131I and 99Y , but
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also for other radionuclides used in therapy, such as 153Sm or 177Lu;
• it can consider the correct density value of the tissue/organ involved (con-
sidered in the macroscopic S-value, S(rT ← rT ));
• it allows to avoid time-consuming CPU-intensive calculations because it
overcomes the mathematical problems linked to the convolution of 3D ar-
rays.
These advantages allow the new method to be routinely used. The pertinence
of the new method for estimating the 3D internal absorbed dose distribution in
the case of a multiexponential kinetics of the radionuclide in the target region is
in course of study. In addiction the follow-up of the patients treated with 99Y -
bearing micro-spheres will be considered and the new method will be used for
calculating the biological parameter α which accounts for the response of the
liver to a fatal damage (double-strand break). Taking into account equation 2.2
and knowing the value of the parameter α, in principle, it could be possible to
choose a tissue absorbed dose D such that the surviving fraction of clonogenic
cells, due to the therapy, will be small enough to ensure the tumor control. The
algorithms which define the radiobiologic models and the quantities derived from
them will be conditioned by this new method for calculating the 3D absorbed
dose distribution.
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A Graphical user interface
Today people interact with computers by using a Graphical User Interface, or
GUI. The computer draws interface components on the screen. The components
include things like windows, scroll bars, menus, buttons, and icons. Usually, a
mouse is used to manipulate such components.
In order to allow an hospital routine use of the new method for 3D dosimetry
a GUI has been implemented by using the Java programming language. Java
programs, which are supposed to run on many different platforms without mod-
ification of the program, use all the standard GUI components. They might vary
a little in appearance from platform to platform, but their functionality should
be identical on any computer where the program runs [53].
The software was developed by using the JAVA SE Development Kit 7, Update
10 (JDK 7u10), which can be downloaded from the website:
http://www.oracle.com/technetwork/java/javase/downloads/index.html.
The NetBeans IDE 7.2.1 has been used. NetBeans IDE is an Integrated Develop-
ment Environment (IDE) available for Windows, Mac, Linux, and Solaris. The
NetBeans project consists of an open-source IDE and an application platform
that enable developers to rapidly create web, enterprise, desktop, and mobile
applications by using whatever programming language. It can been downloaded
from the website:
www.netbeans.org.
The developed software uses the JavaOctave package, a bridge from Java to Oc-
tave, useful to do some Octave calculations from inside a Java application, which
can be downloaded from the website:
http://kenai.com/projects/javaoctave/pages/Home.
By using the NetBeans IDE a Java archive was created which includes all the
.class files, the icons and the Octave functions needed for running the software.
This .jar file can be executed from any Linux platform with the JAVA SE DK
7 and Octave installed. When the program is executed a dialog box is opened
for choosing the file.txt containing the SPECT lesion counts (ci), after another
dialog box is opened for choosing the file.txt containing the SPECT counts in
all the target (C(rT , t)). If no file has been selected an error message will be
displayed. Afterwards a frame will appear such that shown in the figure A.1. In
this frame some graphical components are present: a spinner for setting the mass
value expressed in g; a spinner for setting the administered activity exspressed in
A. Graphical user interface
Figure A.1: Frame of the GUI with all the graphical components and
the confirmation button.
MBq; a spinner for setting the maximum uptake of the radionuclide in the target
region; a drop-down menu for choosing the radionuclide; a spinner for setting the
effective decay time of the radionclide in the target region expressed in h; a text
field for writing the name of the file where saving the DVH with a drop-down
menu for choosing the image format. When all the settings have been chosen a
button appears for confirming as shown in figure A.1.
If a setting is wrong (for example the mass value is setted to zero) an error
message will be displayed as shown in figure A.2, othewise another button appears
for calculating the 3D dose by using the new and straightforward method as shown
in figure A.3. The software returns the image of the DVH which is saved in the
current directory.
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A. Graphical user interface
Figure A.2: Frame of the GUI with all the graphical components and an
error message.
Figure A.3: Frame of the GUI with all the graphical components, the
confirmation button and the start button.
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